Who invested in Scenic Biotech?

Eir Ventures, Vesalius Biocapital and Biomed Partners are named as investors in this round.

Where is Scenic Biotech based and how big is it?

Scenic Biotech is based in Amsterdam, North Holland, Netherlands. Fundz records about 43 employees.

Scenic Biotech secures Series A funding led by EIR Ventures, Vesalius Biocapital, and Biomed Partners to advance modifier therapies for genetic disorders.

PRIVATEMay 20, 2026

Round Type

Series A

AmsterdamBiotechnologyScience And Engineering

Investors

Eir VenturesVesalius BiocapitalBiomed Partners

Description

Scenic Biotech has secured Series A funding, co-led by EIR Ventures, Vesalius Biocapital, and Biomed Partners. This funding aims to enhance their proprietary Cell-Seq platform for developing therapies for severe genetic disorders. The company's unique approach identifies modifier genes, crucial for treating genetic diseases. With prior seed funding and endorsements from major pharma partners, Scenic is set for a significant year ahead.

Quick answer

Scenic Biotech raised an undisclosed amount in a Series A round, dated March 10, 2022. Investors: Eir Ventures, Vesalius Biocapital and Biomed Partners. Scenic Biotech is based in Amsterdam, North Holland, Netherlands.

How much did Scenic Biotech raise?: Scenic Biotech raised an undisclosed amount in a Series A round on March 10, 2022.
Who invested in Scenic Biotech?: Eir Ventures, Vesalius Biocapital and Biomed Partners are named as investors in this round.
What does Scenic Biotech do?: Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention.
Where is Scenic Biotech based and how big is it?: Scenic Biotech is based in Amsterdam, North Holland, Netherlands. Fundz records about 43 employees.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Scenic Biotech that raised within 45 days of this round, from Fundz verified event records.

Unlearn raised $50M on April 19, 2022.
Carlsmed raised $30M (Series B) on April 19, 2022.
Unlearn raised $50M (Series B) on April 19, 2022.
Be Biopharma raised $130M (Funding Round) on April 14, 2022.
CDR-Life raised $76M (Series A) on April 13, 2022.
Surf Bio raised $16M (Seed) on April 12, 2022.

Who to call at Scenic Biotech, and when

A new round usually means Scenic Biotech is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Scenic Biotech raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Scenic Biotech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Scenic Biotech. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Scenic Biotech

Location

Amsterdam, North Holland, Netherlands

About

Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene. As a pioneer in the field, Scenic Biotech is leveraging its Cell-Seq discovery platform to identify genetic modifiers across multiple therapeutic areas. It is building a pipeline of disease modifying therapeutics to treat devastating diseases including inherited rare diseases and cancer. Its lead programs include an immuno-oncology program targeting QPCTL, and three rare diseases programs based on druggable genetic modifiers. The rare disease programs consist of; Niemann Pick disease, type C (NP-C1), a rare lipid storage disorder that affects lipid metabolism, or the way fats, lipids, and cholesterol are transported in human cells, Barth syndrome, an X-linked, lipid metabolism disorder that affects the heart, and a program to treat a severe heritable metabolic syndrome. Scenic Biotech has a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize novel therapeutics that target genetic modifiers. Headquartered in Amsterdam, The Netherlands, Scenic Biotech was founded in 2017 as a spin-out of the Netherlands Cancer Institute, and Oxford University. It is backed by a pan-European syndicate of Venture Capital investors that include Eir Ventures, BioMedPartners, Vesalius Biocapital, BioGeneration Ventures, Inkef Capital and Oxford Science Enterprises. 'Scenic Biotech' refers to all companies within the Scenic group, comprising Scenic Holding BV and its two fully owned subsidiary companies: Scenic Immunology BV and Scenic Biotech BV. For further information, please visit: www.scenicbiotech.com Follow up on LinkedIn

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Scenic Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Predictive Intelligence

Strategic

ML-powered predictions for Scenic Biotech's next move

See what Strategic adds

Funding Insights

What this usually means

Typical timeline to Series B

Series A companies typically raise their next round in 10-18 months

Scenic Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.